Fibromyalgia: Why vagal nerve stimulation is gaining traction

Fibromyalgia is characterised by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. The aetiology remains poorly understood, but central sensitisation is a key feature, leading to amplified pain processing. Current treatments, including analgesics, antidepressants, and exercise, often provide only modest relief, highlighting the need for novel approaches. Neuromodulation, which involves altering nerve activity through electrical or magnetic stimulation, has gained traction as a potential therapeutic strategy for various chronic pain states.¹

A comprehensive review by Gallasch and Thieme, published in Schmerz, examined eight current non-invasive neuromodulation methods and their supporting evidence for chronic pain conditions.¹ This review provides a framework for understanding how these diverse techniques, including transcutaneous electrical nerve stimulation (TENS), transcranial direct current stimulation (tDCS), and vagal nerve stimulation (VNS), might be applied. The authors also explored whether combining neuromodulation with behavioural or psychological pain therapy could enhance therapeutic outcomes, a significant consideration given the biopsychosocial nature of chronic pain.¹

Understanding the Mechanism of Nerve Stimulation

The concept behind nerve stimulation for pain relief centres on modulating neural pathways involved in pain perception. Different neuromodulation techniques target distinct nerves or brain regions to achieve this. For instance, TENS works by delivering low-voltage electrical currents through electrodes placed on the skin, aiming to activate large-diameter afferent nerve fibres, which can inhibit pain signals via the gate control theory of pain. Other methods, like tDCS, apply weak direct currents to the scalp to modulate cortical excitability, influencing pain processing centres in the brain.¹

Vagal nerve stimulation (VNS), specifically transcutaneous VNS (tVNS), warrants clinical attention because it can activate descending pain inhibitory pathways and modulate neurotransmitter release. The vagus nerve is a major component of the autonomic nervous system, playing a significant role in regulating inflammation, mood, and pain. Stimulating the vagus nerve can activate descending pain inhibitory pathways and modulate neurotransmitter release, potentially reducing central sensitisation. This mechanism is particularly relevant for conditions like fibromyalgia, where central sensitisation is a hallmark.¹

Recent literature reframes fibromyalgia from a symptom-centric pharmacologic model to a network-centric neuromodulation approach. A 2025 systematic review highlighted physiological evidence of autonomic imbalance, such as decreased heart rate variability, alongside neuroinflammatory activation and aberrant cortical network connectivity in fibromyalgia patients.⁵ The vagus nerve projects to many brain regions related to pain processing, and its stimulation modulates both vagal activity and neuro-immune communication.⁴ The anti-inflammatory properties of this stimulation may also contribute directly to its pain-inhibitory effects.⁴

This mechanistic framework does not establish clinical efficacy on its own. Identifying aberrant cortical connectivity or decreased heart rate variability in a laboratory setting does not guarantee that correcting these markers will eliminate a patient's pain. Clinicians should explain to patients that while the biological rationale is sound, nerve stimulation is an attempt to retrain a dysregulated system rather than a guaranteed quick fix. The exact relationship between altering these physiological markers and achieving meaningful symptom relief requires direct clinical validation.

Preclinical Evidence and Translational Potential

While direct human trials for tVNS in fibromyalgia are still in early stages, preclinical research offers compelling evidence for its potential. Yadav, Morris, and Conner, writing in JBMR Plus, demonstrated that transcutaneous vagal nerve stimulation improved post-traumatic osteoarthritis pain in mice.² This study, while focused on osteoarthritis, provides significant insights into the analgesic effects of tVNS, showing significant reductions in pain-related behaviours in mice treated with tVNS compared to controls. The researchers observed significant reductions in pain-related behaviours in mice treated with tVNS compared to controls, suggesting a broader applicability of this technique to other chronic pain conditions.²

The translational potential of these preclinical findings to fibromyalgia is substantial. Both post-traumatic osteoarthritis pain and fibromyalgia involve elements of central sensitisation and neuroinflammation. If tVNS can effectively modulate these pathways in one chronic pain model, it stands to reason that similar mechanisms could be leveraged to alleviate fibromyalgia symptoms. The non-invasive nature of tVNS also makes it an attractive option, potentially reducing the risks associated with more invasive neuromodulation techniques.²

Beyond animal models, early human data across various musculoskeletal diseases supports this translational leap. A 2021 review noted that vagus nerve stimulation dampened the inflammatory response of circulatory peripheral cells in rheumatoid arthritis patients and decreased pain in erosive hand osteoarthritis.⁸ The same review highlighted that this stimulation could limit fatigue in Sjogren's syndrome and systemic lupus, alongside decreasing pain in fibromyalgia.⁸

These early observations do not confirm broad utility across all rheumatological conditions. Open-labeled small pilot studies dominate the current literature, leaving a gap for randomized controlled trials versus sham stimulation with large samples of patients to definitively conclude about the efficacy of the intervention.⁸ Physicians tracking these developments should view transcutaneous stimulation as an experimental adjunct rather than a replacement for established therapies, keeping expectations grounded until larger trials report their findings.

The Role of Wearable Technology

The practical application of non-invasive neuromodulation in clinical practice is heavily reliant on advancements in technology, particularly wearable devices. Caffrey, Jeong, and Del Rosario, in their review for the American Journal of Physical Medicine & Rehabilitation, highlighted the current state of wearable devices for bioelectrical stimulation in rehabilitation.³ These devices are making neuromodulation more accessible, user-friendly, and suitable for home use, which is critical for chronic conditions requiring long-term management.

Wearable devices for tVNS, for example, can be discreetly worn and operated by patients, allowing for consistent therapy without frequent clinic visits. This ease of use could significantly improve adherence, a common challenge in chronic pain management. The review noted that these devices often incorporate features like Bluetooth connectivity for data logging and remote monitoring by clinicians, enabling personalised adjustments to treatment parameters.³ Such technological integration could transform how neuromodulation therapies are delivered, moving them from specialised clinics into the daily lives of patients. The development of such devices also opens up possibilities for hypoglossal nerve stimulation for OSA, demonstrating the versatility of bioelectrical approaches.

A scoping review examined 26 publications on transcutaneous auricular vagus nerve stimulation for pain conditions including episodic migraine without aura, rheumatoid arthritis, fibromyalgia, irritable bowel syndrome, and chronic low back pain.⁷ The review found that device type, settings, dosage, and placement of electrodes varied widely across the included studies.⁷ Both invasive and noninvasive devices have been developed, with noninvasive options including stimulation of the auricular or carotid branches of the vagus nerve.⁴

This hardware variability means there is no standardized prescription for a wearable device. The literature lacks data on the optimal dosage for specific pain conditions, measures to evaluate intervention fidelity, and long-term outcomes.⁷ Providers cannot simply prescribe a generic wearable and expect uniform results. They must wait for standardized protocols that define exact stimulation parameters before integrating these devices into routine care.

Combining Neuromodulation with Behavioural Therapy

The Gallasch and Thieme review also emphasized the importance of integrating neuromodulation with behavioural or psychological pain therapy.¹ Chronic pain, especially fibromyalgia, has significant psychological components, including anxiety, depression, and catastrophising, which can amplify pain perception. Combining a physical intervention like nerve stimulation with cognitive behavioural therapy (CBT) or mindfulness-based stress reduction (MBSR) could address both the physiological and psychological dimensions of pain. This multimodal approach aligns with current best practices in chronic pain management, which advocate for holistic, patient-centred care.¹

For instance, neuromodulation might reduce the intensity of pain signals, making it easier for patients to engage in physical therapy or psychological interventions. Conversely, psychological therapies can help patients develop coping strategies, improve pain self-efficacy, and reduce the emotional distress associated with chronic pain, thereby enhancing the overall effectiveness of neuromodulation. This synergistic effect could lead to more sustained and meaningful improvements in quality of life for fibromyalgia patients. The ongoing discussion about adjunctive non-opioid therapies for musculoskeletal pain also highlights the need for comprehensive approaches.

The integration of these therapies aims to address the co-occurring symptoms that often complicate chronic pain management. A review of the literature indicated a growing body of evidence for the effective use of transcutaneous auricular stimulation to reduce co-occurring symptoms, such as depression.⁷ A separate systematic review of 6 studies on vagus nerve stimulation effects in fibromyalgia highlighted improvements in pain, fatigue, sleep disturbance, and autonomic regulation.⁵

Combining treatments complicates the ability to isolate the specific effect of the neuromodulation device. If a patient improves while using a wearable stimulator and attending cognitive behavioural therapy, the exact contribution of the electrical stimulation remains unclear. Clinicians should frame this multimodal approach as a comprehensive management strategy, advising patients that the device is one tool within a broader rehabilitation plan rather than a standalone cure.

Where the Evidence Falls Short (for now)

While the preclinical data and the general principles of neuromodulation are encouraging, the direct evidence for tVNS in fibromyalgia in human trials remains limited. The Gallasch and Thieme review, while comprehensive, primarily synthesises evidence across various chronic pain conditions, not exclusively fibromyalgia.¹ This means that while the mechanisms are plausible, specific efficacy and safety profiles for fibromyalgia patients still require dedicated investigation. The review itself is a summary of existing evidence, not a primary clinical trial.¹

Another caveat lies in the heterogeneity of fibromyalgia itself. Patients present with a wide range of symptoms and varying degrees of severity, making it challenging to design trials that capture a universally effective treatment. The optimal stimulation parameters (frequency, intensity, duration) for tVNS in fibromyalgia are also yet to be definitively established. These parameters can significantly influence therapeutic outcomes, and their individualisation will be key to successful implementation. The lack of large-scale, placebo-controlled trials specifically for tVNS in fibromyalgia means that while the concept is sound, the hard numbers are still pending. This is a common challenge in pain research, where even well-established drugs like cyclobenzaprine, which targets fibromyalgia pain by improving sleep, require careful patient selection. Cyclobenzaprine's mechanism highlights the complexity of addressing fibromyalgia symptoms.

The long-term durability of treatment effects also needs to be assessed. Chronic conditions like fibromyalgia require sustained relief, and it is not yet clear whether the benefits of tVNS persist over extended periods or if patients develop tolerance. While wearable devices enhance accessibility, ensuring proper patient training and adherence to stimulation protocols will be essential for real-world effectiveness. The potential for individual variability in response to neuromodulation also means that not all patients will benefit equally, necessitating careful patient selection and monitoring.

Methodological flaws in current research further limit clinical confidence. A systematic review identified key methodological heterogeneity limiting current interpretability, including variations in stimulation parameters, outcome metrics, the type of control arm, sham definitions, and small sample sizes.⁵ Until adaptive trial designs and the stratification of responders validate this approach as a scalable intervention, the evidence remains preliminary.⁵ Physicians must weigh these trial limitations before recommending out-of-pocket expenditures for unproven devices.

The Path Ahead

The current market of fibromyalgia treatment is ripe for innovation, and non-invasive neuromodulation, particularly tVNS, offers a compelling new direction. The preclinical evidence for its analgesic effects, coupled with advancements in wearable technology, positions it as a strong candidate for future clinical development. The emphasis on combining neuromodulation with behavioural therapies also reflects a more integrated and patient-centred approach to chronic pain management. The next steps involve rigorous, adequately powered clinical trials specifically targeting fibromyalgia patients to establish definitive efficacy, optimal treatment protocols, and long-term safety. Only then can nerve stimulation move from an experimental concept demonstrating preclinical pain reduction to a standard of care for this challenging condition.

A proposed parallel group, sham-controlled, randomized study aims to address these gaps by recruiting 136 fibromyalgia patients with chronic moderate to high pain intensity.⁶ The protocol involves multiple transcutaneous stimulation sessions over the vagal auricular and cervical branches, administered 5 times per week for 4 weeks, with pain intensity as the primary outcome measure.⁶ Secondary measures will include fatigue, health-related quality of life, sleep disorders, depression, heart rate variability, and pro-inflammatory cytokine levels.⁶

A protocol is just a plan. It does not provide results, and the hypothesized normalization of vagal control of nociception and immune-autonomic functions remains untested in this specific cohort.⁶ The authors themselves note they do not predict a difference in results between the auricular and cervical stimulation protocols, which highlights the ongoing uncertainty regarding optimal electrode placement.⁶

For the practicing clinician, the path ahead requires patience. The transition toward a network-centric neuromodulation approach is underway, but it is not yet complete. Physicians should monitor the results of these upcoming large-scale trials while continuing to rely on established, multimodal care plans for their fibromyalgia patients. Recommending unproven hardware before the data matures risks undermining patient trust if the devices fail to deliver meaningful relief.